

2019 Future of Vaso Occlusive Crisis Associated With Sickle Cell Disease R&D Pipeline Drugs and Companies- Analysis of Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/20602425808EN.html>

Date: January 2019

Pages: 75

Price: US\$ 2,199.00 (Single User License)

ID: 20602425808EN

Abstracts

The global demand for Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment options is emerging rapidly driven by consumption in major emerging markets. As more growth opportunities will turn up over the medium to long term future, a large number of companies are working on Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline. Companies quickly adapting to the change and moving their products to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline companies from advancing their products into Phase 3 or Phase 4.

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Report Description

The H1 2019 pipeline review report on Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline is a comprehensive study on the candidates in development across different phases worldwide. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline compounds.

The Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline guide presents information on all active drugs currently being developed for Vaso-Occlusive Crisis Associated With Sickle Cell Disease. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Vaso-Occlusive Crisis Associated With Sickle Cell Disease product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline report includes

An overview of Vaso-Occlusive Crisis Associated With Sickle Cell Disease disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials

etc

Phase wise count of pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Report Guide and Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)
- 3.3 Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)
- 3.4 Companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline, H1- 2019
- 3.5 Mechanism of Action wise Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Candidates

4. ARQULE, INC. VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 4.1 ArQule, Inc. Business Profile
- 4.2 ArQule, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 4.2.1 Drug Snapshot
 - 4.2.1.1 Originator
 - 4.2.1.2 Collaborator/Co-Developer
 - 4.2.1.3 Route of Administration
 - 4.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 4.2.1.5 Area
 - 4.2.1.6 Type of Molecular Entity

- 4.3 Current Status
- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5. ASTRAZENECA PLC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 5.1 AstraZeneca Plc Business Profile
- 5.2 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 5.2.1 Drug Snapshot
 - 5.2.1.1 Originator
 - 5.2.1.2 Collaborator/Co-Developer
 - 5.2.1.3 Route of Administration
 - 5.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 5.2.1.5 Area
 - 5.2.1.6 Type of Molecular Entity
- 5.3 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6. BLUEBIRD BIO, INC. VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 6.1 bluebird bio, Inc. Business Profile
- 6.2 bluebird bio, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 6.2.1 Drug Snapshot
 - 6.2.1.1 Originator
 - 6.2.1.2 Collaborator/Co-Developer
 - 6.2.1.3 Route of Administration
 - 6.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 6.2.1.5 Area
 - 6.2.1.6 Type of Molecular Entity
- 6.3 Current Status

- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7. GLOBAL BLOOD THERAPEUTICS INC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 7.1 Global Blood Therapeutics Inc Business Profile
- 7.2 Global Blood Therapeutics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 7.2.1 Drug Snapshot
 - 7.2.1.1 Originator
 - 7.2.1.2 Collaborator/Co-Developer
 - 7.2.1.3 Route of Administration
 - 7.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 7.2.1.5 Area
 - 7.2.1.6 Type of Molecular Entity
- 7.3 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8. HILLHURST BIOPHARMACEUTICALS INC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 8.1 Hillhurst Biopharmaceuticals Inc Business Profile
- 8.2 Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 8.2.1 Drug Snapshot
 - 8.2.1.1 Originator
 - 8.2.1.2 Collaborator/Co-Developer
 - 8.2.1.3 Route of Administration
 - 8.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 8.2.1.5 Area
 - 8.2.1.6 Type of Molecular Entity
- 8.3 Current Status
- 8.4 Drug Overview

- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9. IMARA INC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 9.1 Imara Inc Business Profile
- 9.2 Imara Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 9.2.1 Drug Snapshot
 - 9.2.1.1 Originator
 - 9.2.1.2 Collaborator/Co-Developer
 - 9.2.1.3 Route of Administration
 - 9.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 9.2.1.5 Area
 - 9.2.1.6 Type of Molecular Entity
- 9.3 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10. MODUS THERAPEUTICS HOLDING AB VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 10.1 Modus Therapeutics Holding AB Business Profile
- 10.2 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 10.2.1 Drug Snapshot
 - 10.2.1.1 Originator
 - 10.2.1.2 Collaborator/Co-Developer
 - 10.2.1.3 Route of Administration
 - 10.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 10.2.1.5 Area
 - 10.2.1.6 Type of Molecular Entity
- 10.3 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details

10.7 Latest Drug Developments

11. NOVARTIS AG VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

11.1 Novartis AG Business Profile

11.2 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details

11.2.1 Drug Snapshot

11.2.1.1 Originator

11.2.1.2 Collaborator/Co-Developer

11.2.1.3 Route of Administration

11.2.1.4 Orphan Drug/Fast Track/Special Designation

11.2.1.5 Area

11.2.1.6 Type of Molecular Entity

11.3 Current Status

11.4 Drug Overview

11.5 Drug Mechanism of Action

11.6 Clinical/Pre-clinical Trial Details

11.7 Latest Drug Developments

12. NUVOX PHARMA LLC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

12.1 NuvOx Pharma LLC Business Profile

12.2 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details

12.2.1 Drug Snapshot

12.2.1.1 Originator

12.2.1.2 Collaborator/Co-Developer

12.2.1.3 Route of Administration

12.2.1.4 Orphan Drug/Fast Track/Special Designation

12.2.1.5 Area

12.2.1.6 Type of Molecular Entity

12.3 Current Status

12.4 Drug Overview

12.5 Drug Mechanism of Action

12.6 Clinical/Pre-clinical Trial Details

12.7 Latest Drug Developments

13. PFIZER INC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 13.1 Pfizer Inc Business Profile
- 13.2 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 13.2.1 Drug Snapshot
 - 13.2.1.1 Originator
 - 13.2.1.2 Collaborator/Co-Developer
 - 13.2.1.3 Route of Administration
 - 13.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 13.2.1.5 Area
 - 13.2.1.6 Type of Molecular Entity
- 13.3 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details
- 13.7 Latest Drug Developments

14. PROLONG PHARMACEUTICALS LLC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 14.1 Prolong Pharmaceuticals LLC Business Profile
- 14.2 Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 14.2.1 Drug Snapshot
 - 14.2.1.1 Originator
 - 14.2.1.2 Collaborator/Co-Developer
 - 14.2.1.3 Route of Administration
 - 14.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 14.2.1.5 Area
 - 14.2.1.6 Type of Molecular Entity
- 14.3 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15. SANCILIO & COMPANY INC VASO-OCCLUSIVE CRISIS ASSOCIATED WITH

SICKLE CELL DISEASE PIPELINE DETAILS

- 15.1 Sancilio & Company Inc Business Profile
- 15.2 Sancilio & Company Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 15.2.1 Drug Snapshot
 - 15.2.1.1 Originator
 - 15.2.1.2 Collaborator/Co-Developer
 - 15.2.1.3 Route of Administration
 - 15.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 15.2.1.5 Area
 - 15.2.1.6 Type of Molecular Entity
- 15.3 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16. SEATTLE GENETICS, INC. VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 16.1 Seattle Genetics, Inc. Business Profile
- 16.2 Seattle Genetics, Inc. Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 16.2.1 Drug Snapshot
 - 16.2.1.1 Originator
 - 16.2.1.2 Collaborator/Co-Developer
 - 16.2.1.3 Route of Administration
 - 16.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 16.2.1.5 Area
 - 16.2.1.6 Type of Molecular Entity
- 16.3 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17. SELEXYS PHARMACEUTICALS CORPORATION VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE PIPELINE DETAILS

- 17.1 Selexys Pharmaceuticals Corporation Business Profile
- 17.2 Selexys Pharmaceuticals Corporation Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Details
 - 17.2.1 Drug Snapshot
 - 17.2.1.1 Originator
 - 17.2.1.2 Collaborator/Co-Developer
 - 17.2.1.3 Route of Administration
 - 17.2.1.4 Orphan Drug/Fast Track/Special Designation
 - 17.2.1.5 Area
 - 17.2.1.6 Type of Molecular Entity
- 17.3 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18. LATEST VASO-OCCLUSIVE CRISIS ASSOCIATED WITH SICKLE CELL DISEASE DRUG PIPELINE DEVELOPMENTS, 2019

19. APPENDIX

- 19.1 About Us
- 19.2 Sources and Methodology
- 19.3 Contact Information

I would like to order

Product name: 2019 Future of Vaso Occlusive Crisis Associated With Sickle Cell Disease R&D Pipeline Drugs and Companies- Analysis of Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/20602425808EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/20602425808EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970